Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMOEM2I)

Drug Name
Estriol Drug Info
Synonyms
Aacifemine; Destriol; Estratriol; Estriel; Estriolo; Gynaesan; Hemostyptanon; Holin; Hormomed; Hormonin; Klimoral; Oestratriol; Oestriol; Oestriolum; Orestin; Orgastyptin; Overstin; Ovestin; Ovestrion; Stiptanon; Synapause; Theelol; Thulol; Tridestrin; Trihydroxyestrin; Trihydroxyoestrin; Triodurin; Triovex; Deuslon A; Estriolo [Italian]; Folicular hormone; Follicular hormone hydrate; Oestriol [Steroidal oestrogens]; A 13610; E0218; OE3; Deuslon-A; Estriel (TN); Estriol [USAN:JAN]; Estriol, unconjugated; Ortho-Gynest; Estriol (JP15/USP); Estra-1,3,5(10)-trien-3,16alpha,17beta-triol; Estra-1,3,5(10)-triene-3,16,17-triol; Estra-1,3,5(10)-triene-3,16alpha,17beta-triol; Oestra-1,3,5(10)-triene-3,16alpha,17beta-triol; Oestra-1,3,5(10)-triene-3,16-alpha,17-beta-triol; Estra-1,3,5(10)-trien-3,16.alpha., 17.beta.-triol; Estra-1,3,5(10)-trien-3,16.alpha.,17.beta.-triol; Estra-1,3,5(10)-triene-3,16.alpha., 17.beta.-triol; Estra-1,3,5(10)-triene-3,16.alpha.,17.beta.-triol; Oestra-1,3,5(10)-triene-3,16.alpha., 17.beta.-triol; Oestra-1,3,5(10)-triene-3,16.alpha.,17.beta.-triol; (16.alpha.,17.beta.)-Estra-1,3,5(10)-triene-3,16,17-triol; (16.alpha.,17.beta.)-Oestra-1,3,5(10)-triene-3,16,17-triol; (16alpha,17beta)-Estra-1,3,5(10)-triene-3,16,17-triol; (16alpha,17beta)-Oestra-1,3,5(10)-triene-3,16,17-triol; 1,3,5(10)-ESTRATRIENE-3,16,17-TRIOL; 1,3,5(10)-Estratriene-3,16-alpha,17beta-triol; 1,3,5(10)-Estratriene-3,16.alpha., 17.beta.-triol; 1,3,5(10)-Estratriene-3,16.alpha.,17.beta.-triol; 1,3,5(10)-Estratriene-3,16alpha,17beta-Triol; 1,3,5-Estratriene-3.beta.,16-.alpha.,17-.beta.-triol; 1,3,5-Estratriene-3beta,16alpha,17beta-triol; 1,3,5-Oestratriene-3-.beta.,16.alpha.,17.beta.-triol; 1,3,5-Oestratriene-3beta,16alpha,17beta-triol; 16,17-Epiestriol; 16-Epiestriol; 16-Hydroxyestradiol; 16-alpha,17-beta-Estriol; 16-alpha,17-beta-Oestriol; 16-alpha-Hydroxyestradiol; 16-alpha-Hydroxyoestradiol; 16.alpha.,17.beta.-Estriol; 16.alpha.,17.beta.-Oestriol; 16.alpha.-Estriol; 16.alpha.-Hydroxy-17.beta.-estradiol; 16.alpha.-Hydroxyestradiol; 16.alpha.-Hydroxyoestradiol; 16alpha,17beta-Estriol; 16alpha,17beta-Oestriol; 16alpha-Hydroxy-17beta-estradiol; 16alpha-Hydroxyestradiol; 16alpha-Hydroxyoestradiol; 3,16-alpha,17-beta-Estriol; 3,16-alpha,17-beta-Oestriol; 3,16-alpha,17-beta-Trihydroxy-delta-1,3,5-estratriene; 3,16-alpha,17-beta-Trihydroxy-delta-1,3,5-oestratriene; 3,16-alpha,17-beta-Trihydroxyestra-1,3,5(10)-triene; 3,16-alpha,17-beta-Trihydroxyoestra-1,3,5(10)-triene; 3,16.alpha.,17.beta.-Estriol; 3,16.alpha.,17.beta.-Trihydroxy-.delta.-1,3,5-estratriene; 3,16.alpha.,17.beta.-Trihydroxy-.delta.-1,3,5-oestratriene; 3,16.alpha.,17.beta.-Trihydroxy-1,3,5(10)-estratriene; 3,16.alpha.,17.beta.-Trihydroxyestra-1,3,5(10)-triene; 3,16alpha,17beta-Estriol; 3,16alpha,17beta-Trihydroxy-1,3,5(10)-estratriene; 3,16alpha,17beta-Trihydroxy-delta-1,3,5-oestratriene; 3,16alpha,17beta-trihydroxy-Delta(1,3,5)-estratriene
Therapeutic ClassEstrogens
Cross-matching ID
PubChem CID
5756
ChEBI ID
CHEMBL193482
CAS Number
CAS 50-27-1
TTD Drug ID
D0Z1FX
VARIDT Drug ID
DR01435
INTEDE Drug ID
DR0646

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
DNA replication 2.30 0.00e+0 34/36 (94.44%) MCM2;MCM6;MCM5;...
Cell cycle 2.14 0.00e+0 110/124 (88.71%) CDC45;PLK1;MCM2;...
Ribosome biogenesis in eukaryotes 2.00 0.00e+0 52/108 (48.15%) NVL;HEATR1;NOP56;...
Fanconi anemia pathway 1.96 0.00e+0 36/54 (66.67%) FANCL;BRCA1;FANCI;...
Spliceosome 1.82 6.77e-3 101/150 (67.33%) FUS;DDX42;PUF60;...
Notch signaling pathway 1.71 2.66e-2 49/59 (83.05%) TLE4;CTBP1;NOTCH1;...
Fat digestion and absorption -1.64 4.93e-2 35/43 (81.4%) APOB;MTTP;ABCA1;...
Pathogenic Escherichia coli infection -1.65 4.31e-2 152/197 (77.16%) HCLS1;ARPC3;BAK1;...
Amino sugar and nucleotide sugar metabolism -1.66 4.20e-2 38/48 (79.17%) PMM2;NANS;GALE;...
Ovarian steroidogenesis -1.66 4.03e-2 41/51 (80.39%) HSD17B2;CYP11A1;PTGS2;...
Kaposi sarcoma-associated herpesvirus infection -1.67 4.13e-2 172/193 (89.12%) NFKB1;TRADD;EIF2AK2;...
Glycerolipid metabolism -1.67 3.64e-2 44/61 (72.13%) DGKB;TKFC;PNPLA2;...
PD-L1 expression and PD-1 checkpoint pathway in cancer -1.69 3.48e-2 79/89 (88.76%) PPP3R1;MAP2K3;CD247;...
NOD-like receptor signaling pathway -1.72 2.25e-2 145/181 (80.11%) PLCB1;FADD;ANTXR1;...
Glutathione metabolism -1.72 2.36e-2 43/57 (75.44%) GGT5;GSTA4;GSTO1;...
Various types of N-glycan biosynthesis -1.73 2.18e-2 26/39 (66.67%) MGAT1;DDOST;B4GALT3;...
Viral protein interaction with cytokine and cytokine re... -1.75 1.68e-2 84/100 (84%) CCL7;IL10;IL2RA;...
PPAR signaling pathway -1.76 1.54e-2 66/74 (89.19%) ILK;PLIN1;ACSL6;...
N-Glycan biosynthesis -1.77 1.28e-2 38/50 (76%) ALG6;ALG5;ST6GAL1;...
Legionellosis -1.79 1.09e-2 51/57 (89.47%) RAB1A;CASP8;CXCL1;...
Apoptosis -1.79 1.16e-2 126/168 (75%) MAP2K2;CAPN1;PIK3CA;...
Th17 cell differentiation -1.79 1.14e-2 95/107 (88.79%) IL6R;RXRB;HLA-DOB;...
NF-kappa B signaling pathway -1.81 1.12e-2 90/104 (86.54%) BIRC2;LCK;BCL2L1;...
Cytokine-cytokine receptor interaction -1.81 1.21e-2 246/295 (83.39%) CCL7;IL10;IL2RA;...
Collecting duct acid secretion -1.83 1.06e-2 22/27 (81.48%) ATP4B;ATP6V1A;ATP4A;...
Malaria -1.84 1.16e-2 44/50 (88%) TGFB1;SDC2;THBS2;...
Folate biosynthesis -1.90 9.70e-3 23/26 (88.46%) AKR1B10;GGH;GCH1;...
Arachidonic acid metabolism -1.90 9.09e-3 48/61 (78.69%) TBXAS1;PTGES2;CYP4F3;...
Steroid hormone biosynthesis -2.01 2.08e-3 43/61 (70.49%) HSD3B2;COMT;CYP19A1;...
TNF signaling pathway -2.01 2.42e-3 103/112 (91.96%) NFKB1;TRADD;CXCL5;...
Ferroptosis -2.02 2.91e-3 36/41 (87.8%) SAT1;ACSL6;ACSL3;...
Hematopoietic cell lineage -2.02 3.64e-3 90/99 (90.91%) IL6R;HLA-DOB;IL7;...
Mineral absorption -2.05 4.85e-3 48/60 (80%) FTL;MT1E;ATOX1;...
Epithelial cell signaling in Helicobacter pylori infect... -2.20 0.00e+0 62/70 (88.57%) ATP6V1E1;SRC;ATP6V1C1;...
Rheumatoid arthritis -2.26 0.00e+0 78/93 (83.87%) CXCL5;ATP6V1A;CTSL;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 6.66uM 6H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.04uM - 20uM 6H, 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 3H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 6H, 24H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 20uM 6H, 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 0.04uM - 10uM 6H, 24H
Hepatocellular carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HuH-7 CVCL_0336 Homo sapiens 12uM 72H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.01uM - 10uM 6H, 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 0.04uM - 10uM 6H, 24H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.01uM - 20uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 6H, 24H